ONCY CFO granted 260,000 stock options at $1.06

ONCOLYTICS BIOTECH INC Chief Financial Officer Kirk Look received a grant of stock options covering 260,000 common shares as compensation.

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC Chief Financial Officer Kirk Look received a grant of stock options covering 260,000 common shares as compensation. The options have an exercise price of $1.06 per share, equal to the closing price on June 1, 2026, and expire on June 1, 2036.

The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, contingent on his continued service or employment on each vesting date. This filing reflects a routine equity incentive grant, with no open-market share purchases or sales reported.

Insider Trade Summary

Grant/Award: 260,000 shares

Grant/Award 1 txn

Insider Look Kirk

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	260,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 260,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Stock options granted: 260,000 options Exercise price: $1.06 per share Underlying shares: 260,000 common shares +2 more

5 metrics

Stock options granted 260,000 options Grant to CFO on June 1, 2026

Exercise price $1.06 per share Equal to Nasdaq closing price on June 1, 2026

Underlying shares 260,000 common shares Shares issuable upon option exercise

Expiration date June 1, 2036 Option term for CFO grant

Post-grant derivative holdings 260,000 options Total options held following this transaction

Key Terms

Stock Option, exercise price, vests in three equal annual installments, expiration date

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments with the first tranche vesting"

expiration date financial

"expiration_date: "2036-06-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ONCY CFO Kirk Look report on this Form 4?

Kirk Look reported receiving a grant of stock options for 260,000 common shares as compensation. These options give him the right to buy ONCY shares at a fixed price in the future, subject to vesting conditions and an expiration date.

What is the exercise price of the ONCY stock options granted to the CFO?

The options have an exercise price of $1.06 per share, matching the Nasdaq Capital Market closing price on June 1, 2026. This means he can later purchase shares at $1.06 regardless of future market prices, once the options vest.

How many ONCY shares are covered by the stock option grant to the CFO?

The grant covers 260,000 common shares of ONCOLYTICS BIOTECH INC through stock options. Each option corresponds to one underlying common share, giving the CFO potential future ownership if he exercises the options after they vest.

When do the ONCY stock options granted to the CFO start vesting?

The options vest in three equal annual installments, with the first tranche vesting on June 1, 2027. Vesting is conditioned on the CFO’s continued service or employment on each vesting date, aligning the incentive with long-term commitment.

When do the ONCY stock options granted to the CFO expire?

The stock options expire on June 1, 2036, giving a ten-year term from the grant date. After that expiration date, any unexercised options become worthless, so the CFO must exercise vested options before that deadline to acquire shares.

Did the ONCY CFO buy or sell common shares on the open market in this filing?

No open-market purchases or sales of common shares are reported in this filing. The Form 4 shows a compensation-related grant of stock options only, coded as an acquisition (A), with no corresponding sale or tax-withholding disposition transactions disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Look Kirk

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		260,000		(2)	06/01/2036	Common Shares	260,000	$0	260,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)